Managing toxicities in patients on ceritinib therapy


Managing toxicities in patients on ceritinib therapy

Share this page

The management of patients on therapies is an important part of the lung cancer nurse specialist role. This article focuses on the use of ceritinib in patients with ALK-positive non-small cell lung cancer who have previously been treated with crizotinib, the common toxicities that may arise and how to manage them in order to improve patient experience and adherence to treatment.

Want the full article and instant web access?

Explore more and be inspired with a subscription for this journal

  • 1000's of clinical and research articles
  • Interactive CPD articles
  • RCNi portfolio for revalidation

Subscribe now

Already a subscriber? Sign In

Institutional subscriber? This article is currently only available to readers that have a personal subscription. Please click here to be redirected to the institutional site for this journal.